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To the Editor:
Matrix Metalloproteinases (MMPs) are a
family of extracellular matrix degradative enzymes
physiologically involved in tissue development and
remodeling. Now they are being widely studied for
their potential role in the progression and metastasis
of many tumors (1).
Indeed degradation of extracellular matrix is
one of the crucial and early steps in many carcinomas.
The role of the huge family of these enzymes and their
inhibitors in cancer cells invasion, metastasis (2), pro-
liferation and angiogenesis (3) is probably much more
complex than it seems and still needs to be clarified.
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On these basis, many authors paid attention to
the overexpression of MMPs enzymes in renal cell
carcinoma (RCC). Overexpression of MMP2 and
MMP9 has been described in association with poor
prognosis of patients with RCC (4-6). Overexpression
of MMP1, MMP3, MMP7, MMP11, MMP12 and
MMP14 has been described in tissue of RCC (7,8).
More recently, a strong relation between MMP10 ex-
pression and stage and grade of RCC has been demon-
strated (9).
These growing evidences of MMPs role in
RCC pathogenesis is the strong rationale to plan ge-
netic investigation to assess not only the phenotype
but the genotype modification that stand behind RCC
development and progression.
The genetic population based studies are
mainly aimed at identifying groups at a higher risk of
developing a cancer or at a higher risk of having a
cancer with a worse prognosis. The case control popu-
lation based researches are often biased by not con-
trollable factors especially when the sample size is
limited. Moreover, the results of genetic studies are
complicated by the wide heterogeneity between dif-
ferent ethnic groups. To draw any conclusion from
genetic statistics we need wide sample sizes, from
different regions to compare the results of different
ethnic groups.
The efforts and the costs of such studies are
worthy. Indeed the future possibility of identifying a
high-risk group for RCC by a simple test for genetic
polymorphism will lead to an early diagnosis of can-
cer in these patients. The people bearing the high-
risk alleles will take advantage of a strict clinical sur-
veillance for example with periodic ultrasound scan.
Even if the results of the authors do not al-
low identifying an increased risk of RCC for the
MMP1 promoter polymorphism in Brazil, they are
still important. If further data support these results,
the geneticists will have to search for more loci in
order to identify one or more gene polymorphisms
responsible for increased risk of RCC in Brazil. If
further data do not support the result of the afore-
mentioned study, the geneticists will have to plan a
wider population based study to answer to the ques-
tion about the MMP1 promoter polymorphism and
the risk of RCC in Brazil.
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